Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer

Nat Rev Rheumatol. 2021 Sep;17(9):577-578. doi: 10.1038/s41584-021-00654-7. Epub 2021 Jul 5.

Authors

Allen Y Chen^{1

2}, Jedd D Wolchok^{2

3}, Anne R Bass^{4

5}

Affiliations

¹ Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA.
² Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
³ Human Oncology and Pathogenesis Program, Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA. bassa@hss.edu.
⁵ Department of Medicine, Weill Cornell Medicine, New York, NY, USA. bassa@hss.edu.

PMID: 34226728
DOI: 10.1038/s41584-021-00654-7

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Immune Checkpoint Inhibitors*
Immunotherapy
Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors